Saturday 17 October 2026
Export CMND’s income statement to Excel — free account
Clearmind Medicine Inc.
CMND Healthcare Biotechnology
In the quarter to July 2026, EPS grew 99.4%, free cash flow fell 77.9% and total debt rose 10,410.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.26
0.16
−2.49%
Follow CMND
| Oct '18 | Oct '19 | Oct '20 | Oct '21 | Oct '22 | Oct '23 | Oct '24 | Oct '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
10.80 | 0.09 | 24.85 | 0.23 | 0.23 | 1.17 | 1.72 | 1.22 |
Net Debt/EBITDA |
0.00 | 0.01 | 1.41 | 0.10 | 0.05 | 0.88 | 1.19 | 0.68 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 4.63% | 0.00% | 0.23% | 28.93% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | (0.03) | 0.00 | 0.01 | 1.48 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.54 | 0.60 | 1.13 | 0.31 | 0.54 | 0.73 | 0.92 | 1.23 |
Capex/Depreciation |
— | — | — | 0.00 | (0.25) | 0.00 | 0.00 | 0.00 |
Interest Coverage |
— | — | — | (219.71) | (408.59) | (578.29) | (158.70) | — |
| 0.00% | (56.20%) | (73.55%) | 140.81% | 116.23% | 14,074.78% | (256.88%) | (179.39%) | |
| 0.00% | (49.32%) | (67.35%) | (1,158.81%) | (809.93%) | (254.31%) | (79.56%) | (57.83%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(261.07%) | 258.09% | (72.97%) | 464.38% | 464.37% | (1,043.05%) | (177.72%) | (364.83%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.18 | 0.16 | 0.02 | 0.01 | 0.02 |
Share Based Compensation of Revenue |
— | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(7.46) | (3.88) | (10.99) | (73.99) | (37,301.00) | (12,603.00) | (622.91) | (372.80) |
Cash per Share |
5.21 | 0.04 | 13.70 | 11.06 | 3,225.00 | 11,027.80 | 879.90 | 439.80 |
Shareholders Equity per Share |
16.90 | 8.24 | 20.74 | (37.95) | (11,060.00) | 1,967.00 | 398.41 | 93.91 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
16.90 | 8.24 | 20.74 | (37.95) | (11,060.00) | 1,967.00 | 398.41 | 93.91 |
Free Cash Flow |
(0.08) | (0.05) | (0.20) | (2.29) | (3.73) | (6.30) | (4.86) | (4.73) |
Working Capital |
0.06 | (0.03) | 0.24 | (1.59) | (1.50) | 0.82 | 2.96 | 1.06 |
Capital Expenditures |
(0.10) | (0.01) | (0.01) | (0.19) | (0.01) | — | — | — |
Net Current Asset Value |
0.06 | (0.03) | 0.24 | (1.59) | (1.50) | 0.82 | 2.94 | 1.06 |
| Other line items | ||||||||
Quick Ratio |
10.82 | 0.09 | 24.84 | 0.22 | 0.22 | 1.16 | 1.71 | 1.21 |
Depreciation/Fixed assets |
— | — | — | 0.15 | 1.74 | 13.00 | 0.00 | 0.00 |
Cash ROIC |
(33.76%) | (46.84%) | (31.90%) | 275.22% | 500.52% | (96.98%) | (48.65%) | (55.45%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(7.46) | (3.88) | (10.99) | (73.99) | (37,245.00) | (12,603.00) | (622.91) | (372.80) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | (56.00) | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | 0.00 | 0.00 | 0.05 | 0.10 | 0.17 | 0.21 | 0.25 |
Average Payables |
— | — | — | — | — | 1.01 | 0.57 | 0.60 |
Average Assets |
— | 0.16 | 0.26 | 0.63 | 0.85 | 3.39 | 6.60 | 6.67 |
Average Common Equity |
— | 0.14 | 0.24 | (5.19) | (5.93) | (0.06) | 2.05 | 2.15 |
Capex to Sales |
— | — | — | — | 0.00 | — | — | — |
Columns are period end dates